Breast cancer drug adherence under the microscope: will patients stick with treatment?
NCT ID NCT07531693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study tracks 200 women with high-risk HR+/HER2- early breast cancer to see how many continue taking abemaciclib six months after starting. Researchers will review therapy data from 2023 to 2025. The goal is to understand real-world persistence, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib
What this could lead to
If successful, this study could help doctors understand why some patients stop taking abemaciclib early, potentially leading to better support and improved treatment adherence.
What could go wrong
This is an observational study, not a treatment trial. It only looks back at existing data, so it cannot prove what causes patients to stop therapy or improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- TAYLOR-002: Adaptive Breast Cancer Trial (NCT07616453)
- TAYLOR-003: Fovinaciclib for HR+/HER2+ Breast Ca NCT07616427
- Ribociclib vs Chemo for HR+ Breast Cancer (NCT04055493)
- Study on Coaching for Abemaciclib Adherence in B NCT07521202
- ctDNA-Guided Ribociclib vs Chemo for Early Breas NCT07423611
- CDK4/6 Inhibitors for High-Risk Breast Cancer (NCT07019363)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••